OUR PORTFOLIO OF TECHNOLOGIES
*In Mid-Stage Development—
Resusix™ is a dehydrated, pathogen inactivated human plasma-based therapeutic for use in resuscitation. It combines different technologies to form a shelf-stable pharmaceutical grade plasma-derived therapeutic that can be used to replace volume lost in bleeding, while maintaining functional blood clotting factors. Resusix™ is scheduled for an investigational new drug (IND) application submission in Q3 2011.
Stasix® is a freeze-dried, fixed human platelet-derived hemostatic agent that can be rapidly and conveniently rehydrated and infused when bleeding is caused by low platelet counts or platelet dysfunction. By preserving cellular function, we hope to provide a preferred alternative to liquid–stored, banked platelets in terms of bacterial safety, antigenicity, and predictable, consistent function. Stasix® is in pre-clinical development.
Portable Coagulation Monitor (PCM) is a handheld, point-of-care device, intended for use in the rapid assessment of clotting disorders. Its portability, ease of use, and rapid results are important advancements over the current complex and time-consuming procedure. The PCM has significant potential for use in emergency medicine, obstetric and general surgery applications. It is designed to provide rapid, real-time assessment of disorders in coagulation and empirical evidence of trauma-induced coagulopathy and response to therapy. The PCM is slated for 510(k) submission in Q2 2012.
*These products are not available for sale, and the discussions here represent development goals and are not intended to represent marketing statements or claims.
In Early-Stage Development—
Dry Hemostatic Patch is intended to be a resorbable, composite hemostatic surgical aid that delivers concentrated clotting factors to surgical sites, with the convenience of a gauze pad.
Cell-Based Targeted Drug Delivery and Imaging exploits the
properties of platelets to selectively adhere to sites of injury and inflammation. By attaching drugs or imaging agents to platelet membranes, we can deliver high concentrations of drug and contrast agents to solid tumors and sites of vascular breach.
Contract R&D—
Entegrion provides contract research and development services to the Department of Defense to solve refractory problems in blood storage, blood safety, and blood utilization.
In The Market—
Stasilon® is a dual fiber, minimally adherent hemostatic textile that supports rapid hemostasis of bleeding surfaces. Stasilon Orders: 877-877-2533.